Trial delivery, speed and quality
We deliver clinical trials with speed, efficiency, and a focus on high-quality outcomes. Our experienced teams and established hospital based site network ensure reliable performance and consistent delivery for sponsors.
Site Capability & Experience
Speed & Quality
At ACTT, we understand the importance of speed during the feasibility and set up and we strive to ensure trial activation occurs as fast as possible.
- KPI 90 days to SIV ready
- Median contracting cycle time: 44 days
- Rapid FPI track record across multiple specialties
- Centralised contracting and budgeting

Centralised Start-up Team
With strong expertise in New Zealand requirements, we ensure all studies meet Health and Disability Ethics Committee (HDEC) and Medsafe regulatory standards, supporting timely approvals and full compliance.
By centralising these processes, we reduce start-up timelines, minimise administrative burden on investigators, and enable studies to commence smoothly and efficiently.
Recruitment
****UPDATE
Participant retention consistently above 90%
Nationwide access to inpatient and outpatient populations
Get a feasibility response with in 48-72 hours.
Our Investigators
How we work with our investigators
We work in partnership with highly experienced Subject matter experts (SMEs) across a broad range of therapeutic areas, bringing deep clinical expertise and strong research leadership to every study.
Our SMEs are respected specialists within their fields, actively contributing to clinical practice, research innovation, and the advancement of evidence-based medicine in Aotearoa New Zealand and internationally.
Each trial also has a Project Agreement in place – between the Principal Investigator and ACTT.
This agreement confirms:
- Details of the trial including site staffing and sub-investigators
- The target number of participants
- The recruitment timelines
- A recruitment plan to ensure that the target is met
Our Investigators & Departments
View Investigator Publications
Strong engagment with global partners ensures fast study start times up are met, participants recruited to target and excellent quality data produced.
World-class Facilities
![]() |
Laboratory We have a purpose-built laboratory for sample processing and is complete with temperature monitored freezers, refrigerators, and centrifuges. |
![]() |
Reconstitution Capability Dedicated Pharmacy Reconstitution Unit, designed to meet the growing demand for accurate and compliant preparation of investigational products. The unit enables the safe reconstitution and handling of sterile produces – enhancing oversight, quality, and efficiency in complex clinical trials. |
![]() |
Pharmacy We have our own onsite pharmacies and dedicated research pharmacists to ensure IP protocols are followed tightly. Our pharmacies boast secure and temperature-controlled environments to ensure safe storage of all IP. |
![]() |
Clinic Rooms and Infusion Suite All trials are conducted in dedicated clinic rooms based within the public hospital. Each room is equipped with stadiometers, scales, vital signs monitors, and examination beds. Purpose-built infusion suite with two infusion chairs, allowing for the safe and efficient administration of infusion therapies within a controlled, patient-focused environment. |
![]() |
Phase I Overnight Unit Dedicated Phase I overnight located within the hospital. This allows participants to seamlessly transition from our infusion suite to the overnight facility, where 24/7 clinical oversight is provided by experienced staff. |
Case Studies
- Obesity and CVD Phase III – 25 participants over 6 months. Retention 96%, 67% males and 33% females
- Older age and obesity Phase III – randomised 433% to target with 100% retention
- COVID and Flu Vaccine Phase III – 60 participants randomised in 6 days
- Chronic Kidney Disease Phase II – randomised 140% to target with 82% retention
- Paediatric Vaccine Phase III – randomised 212% to target with 100% retention
- Hepatitis B Virus Phase II – randomised 5 participants with 5 weeks with 80% retention
- Obesity Phase II – 28 participant recruited, and 92% retention
- Eosinophilic esophagitis Phase III – randomised 200% target
- Sjogren’s syndrome Phase III – first in Asia-Pacific to enrol a participant
- Idiopathic pulmonary fibrosis Phase III – first to enrol in NZ, second in AUS-NZ
- Breast cancer – first to enrol in NZ, FPI 18 days from activation





